Here, we present plasma NFL/Aβ1–42 as a plasma-based primary screening biomarker reflecting brain neurodegeneration and amyloid pathology in AD that can be used for monitoring disease progression, early diagnosis, and in studies on early disease treatment. This evidence concerns the gene NEFL and amyloidosis.